The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. (March 2020)
- Record Type:
- Journal Article
- Title:
- The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. (March 2020)
- Main Title:
- The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- Authors:
- Sepanlou, Sadaf G
Safiri, Saeid
Bisignano, Catherine
Ikuta, Kevin S
Merat, Shahin
Saberifiroozi, Mehdi
Poustchi, Hossein
Tsoi, Derrick
Colombara, Danny V
Abdoli, Amir
Adedoyin, Rufus Adesoji
Afarideh, Mohsen
Agrawal, Sutapa
Ahmad, Sohail
Ahmadian, Elham
Ahmadpour, Ehsan
Akinyemiju, Tomi
Akunna, Chisom Joyqueenet
Alipour, Vahid
Almasi-Hashiani, Amir
Almulhim, Abdulaziz M
Al-Raddadi, Rajaa M
Alvis-Guzman, Nelson
Anber, Nahla Hamed
Angus, Colin
Anoushiravani, Amir
Arabloo, Jalal
Araya, Ephrem Mebrahtu
Asmelash, Daniel
Ataeinia, Bahar
Ataro, Zerihun
Atout, Maha Moh'd Wahbi
Ausloos, Floriane
Awasthi, Ashish
Badawi, Alaa
Banach, Maciej
Bejarano Ramirez, Diana Fernanda
Bhagavathula, Akshaya Srikanth
Bhala, Neeraj
Bhattacharyya, Krittika
Biondi, Antonio
Bolla, Srinivasa Rao
Boloor, Archith
Borzì, Antonio M
Butt, Zahid A
Cámera, Luis LA Alberto
Campos-Nonato, Ismael R
Carvalho, Félix
Chu, Dinh-Toi
Chung, Sheng-Chia
Cortesi, Paolo Angelo
Costa, Vera M
Cowie, Benjamin C
Daryani, Ahmad
de Courten, Barbora
Demoz, Gebre Teklemariam
Desai, Rupak
Dharmaratne, Samath Dhamminda
Djalalinia, Shirin
Do, Hoa Thi
Dorostkar, Fariba
Drake, Thomas M
Dubey, Manisha
Duncan, Bruce B
Effiong, Andem
Eftekhari, Aziz
Elsharkawy, Aisha
Etemadi, Arash
Farahmand, Mohammad
Farzadfar, Farshad
Fernandes, Eduarda
Filip, Irina
Fischer, Florian
Gebremedhin, Ketema Bizuwork Bizuwork
Geta, Birhanu
Gilani, Syed Amir
Gill, Paramjit Singh
Gutirrez, Reyna Alma
Haile, Michael Tamene
Haj-Mirzaian, Arvin
Hamid, Saeed S
Hasankhani, Milad
Hasanzadeh, Amir
Hashemian, Maryam
Hassen, Hamid Yimam
Hay, Simon I
Hayat, Khezar
Heidari, Behnam
Henok, Andualem
Hoang, Chi Linh
Hostiuc, Mihaela
Hostiuc, Sorin
Hsieh, Vivian Chia-rong
Igumbor, Ehimario U
Ilesanmi, Olayinka Stephen
Irvani, Seyed Sina Naghibi
Jafari Balalami, Nader
James, Spencer L
Jeemon, Panniyammakal
Jha, Ravi Prakash
Jonas, Jost B
Jozwiak, Jacek Jerzy
Kabir, Ali
Kasaeian, Amir
Kassaye, Hagazi Gebremedhin
Kefale, Adane Teshome
Khalilov, Rovshan
Khan, Muhammad Ali
Khan, Ejaz Ahmad
Khater, Amir
Kim, Yun Jin
Koyanagi, Ai
La Vecchia, Carlo
Lim, Lee-Ling
Lopez, Alan D
Lorkowski, Stefan
Lotufo, Paulo A.
Lozano, Rafael
Magdy Abd El Razek, Muhammed
Mai, Hue Thi
Manafi, Navid
Manafi, Amir
Mansournia, Mohammad Ali
Mantovani, Lorenzo Giovanni
Mazzaglia, Giampiero
Mehta, Dhruv
Mendoza, Walter
Menezes, Ritesh G
Mengesha, Melkamu Merid
Meretoja, Tuomo J
Mestrovic, Tomislav
Miazgowski, Bartosz
Miller, Ted R
Mirrakhimov, Erkin M
Mithra, Prasanna
Moazen, Babak
Moghadaszadeh, Masoud
Mohammadian-Hafshejani, Abdollah
Mohammed, Shafiu
Mokdad, Ali H
Montero-Zamora, Pablo A
Moradi, Ghobad
Naimzada, Mukhammad David
Nayak, Vinod
Negoi, Ionut
Nguyen, Trang Huyen
Ofori-Asenso, Richard
Oh, In-Hwan
Olagunju, Tinuke O
Padubidri, Jagadish Rao
Pakshir, Keyvan
Pana, Adrian
Pathak, Mona
Pourshams, Akram
Rabiee, Navid
Radfar, Amir
Rafiei, Alireza
Ramezanzadeh, Kiana
Rana, Saleem Muhammad M
Rawaf, Salman
Rawaf, David Laith
Reiner, Robert C
Roever, Leonardo
Room, Robin
Roshandel, Gholamreza
Safari, Saeed
Samy, Abdallah M
Sanabria, Juan
Sartorius, Benn
Schmidt, Maria Inês
Senthilkumaran, Subramanian
Shaikh, Masood Ali
Sharif, Mehdi
Sharifi, Amrollah
Shigematsu, Mika
Singh, Jasvinder A.
Soheili, Amin
Suleria, Hafiz Ansar Rasul
Teklehaimanot, Berhane Fseha
Tesfay, Berhe Etsay
Vacante, Marco
Vahedian-Azimi, Amir
Valdez, Pascual R
Vasankari, Tommi Juhani
Vu, Giang Thu
Waheed, Yasir
Weldegwergs, Kidu Gidey
Werdecker, Andrea
Westerman, Ronny
Wondafrash, Dawit Zewdu
Wondmieneh, Adam Belay
Yeshitila, Yordanos Gizachew
Yonemoto, Naohiro
Yu, Chuanhua
Zaidi, Zoubida
Zarghi, Afshin
Zelber-Sagi, Shira
Zewdie, Kaleab Alemayehu
Zhang, Zhi-Jiang
Zhao, Xiu-Ju
Naghavi, Mohsen
Malekzadeh, Reza
… (more) - Abstract:
- Summary: Background: Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories. Methods: We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the basis of hospital and claims data. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost due to premature death and years lived with disability. Estimates are presented as numbers and age-standardised or age-specific rates per 100 000 population, with 95% uncertainty intervals (UIs). All estimates are presented for five causes of cirrhosis: hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), and other causes. We compared mortality, prevalence, and DALY estimates with those expected according to the Socio-demographic Index (SDI) as a proxy for the development status of regions and countries. Findings: In 2017, cirrhosis caused more than 1·32 million (95% UI 1·27–1·45) deaths (440 000 [416 000–518 000; 33·3%] in females and 883 000Summary: Background: Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories. Methods: We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the basis of hospital and claims data. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost due to premature death and years lived with disability. Estimates are presented as numbers and age-standardised or age-specific rates per 100 000 population, with 95% uncertainty intervals (UIs). All estimates are presented for five causes of cirrhosis: hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), and other causes. We compared mortality, prevalence, and DALY estimates with those expected according to the Socio-demographic Index (SDI) as a proxy for the development status of regions and countries. Findings: In 2017, cirrhosis caused more than 1·32 million (95% UI 1·27–1·45) deaths (440 000 [416 000–518 000; 33·3%] in females and 883 000 [838 000–967 000; 66·7%] in males) globally, compared with less than 899 000 (829 000–948 000) deaths in 1990. Deaths due to cirrhosis constituted 2·4% (2·3–2·6) of total deaths globally in 2017 compared with 1·9% (1·8–2·0) in 1990. Despite an increase in the number of deaths, the age-standardised death rate decreased from 21·0 (19·2–22·3) per 100 000 population in 1990 to 16·5 (15·8–18·1) per 100 000 population in 2017. Sub-Saharan Africa had the highest age-standardised death rate among GBD super-regions for all years of the study period (32·2 [25·8–38·6] deaths per 100 000 population in 2017), and the high-income super-region had the lowest (10·1 [9·8–10·5] deaths per 100 000 population in 2017). The age-standardised death rate decreased or remained constant from 1990 to 2017 in all GBD regions except eastern Europe and central Asia, where the age-standardised death rate increased, primarily due to increases in alcohol-related liver disease prevalence. At the national level, the age-standardised death rate of cirrhosis was lowest in Singapore in 2017 (3·7 [3·3–4·0] per 100 000 in 2017) and highest in Egypt in all years since 1990 (103·3 [64·4–133·4] per 100 000 in 2017). There were 10·6 million (10·3–10·9) prevalent cases of decompensated cirrhosis and 112 million (107–119) prevalent cases of compensated cirrhosis globally in 2017. There was a significant increase in age-standardised prevalence rate of decompensated cirrhosis between 1990 and 2017. Cirrhosis caused by NASH had a steady age-standardised death rate throughout the study period, whereas the other four causes showed declines in age-standardised death rate. The age-standardised prevalence of compensated and decompensated cirrhosis due to NASH increased more than for any other cause of cirrhosis (by 33·2% for compensated cirrhosis and 54·8% for decompensated cirrhosis) over the study period. From 1990 to 2017, the number of prevalent cases more than doubled for compensated cirrhosis due to NASH and more than tripled for decompensated cirrhosis due to NASH. In 2017, age-standardised death and DALY rates were lower among countries and territories with higher SDI. Interpretation: Cirrhosis imposes a substantial health burden on many countries and this burden has increased at the global level since 1990, partly due to population growth and ageing. Although the age-standardised death and DALY rates of cirrhosis decreased from 1990 to 2017, numbers of deaths and DALYs and the proportion of all global deaths due to cirrhosis increased. Despite the availability of effective interventions for the prevention and treatment of hepatitis B and C, they were still the main causes of cirrhosis burden worldwide, particularly in low-income countries. The impact of hepatitis B and C is expected to be attenuated and overtaken by that of NASH in the near future. Cost-effective interventions are required to continue the prevention and treatment of viral hepatitis, and to achieve early diagnosis and prevention of cirrhosis due to alcohol-related liver disease and NASH. Funding: Bill & Melinda Gates Foundation. … (more)
- Is Part Of:
- Lancet gastroenterology and hepatology. Volume 5:Number 3(2020)
- Journal:
- Lancet gastroenterology and hepatology
- Issue:
- Volume 5:Number 3(2020)
- Issue Display:
- Volume 5, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 5
- Issue:
- 3
- Issue Sort Value:
- 2020-0005-0003-0000
- Page Start:
- 245
- Page End:
- 266
- Publication Date:
- 2020-03
- Journal URLs:
- http://www.sciencedirect.com/ ↗
- DOI:
- 10.1016/S2468-1253(19)30349-8 ↗
- Languages:
- English
- ISSNs:
- 2468-1253
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.081000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12887.xml